LOC14
Based on 5 publication(s) in Google Scholar
LOC14 is a potent Protein disulfide isomerase (PDI) inhibitor with EC50 and Kd values of 500 nM and 62 nM, respectively. LOC14 exhibits high stability in mouse liver microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding. LOC14 inhibits PDIA3 activity, decreases intramolecular disulfide bonds and subsequent oligomerization (maturation) of HA in lung epithelial cells.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.0%
- CAS No.: 877963-94-5
- 화학식: C16H19N3O2S
- 분자량:317.41
-
보관:
4°C, protect from light
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) LOC14
More
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Biological Activity
Kd: 62 nM (PDI)[1]
LOC14 (0.01-100 μM; 24 hours) exhibits the capacity to inhibit recombinant (r)PDIA3 at an IC50 of approximately 5 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MTEC cells
-
Concentration:0.01 μM; 0.1 μM; 0.5 μM; 1 μM; 5 μM; 10 μM; 100 μM
-
Incubation Time:24 hours
-
Result:Inhibited recombinant (r)PDIA3 activity.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male N171–82Q HD mice[2]
-
Dosage:20 mg/kg
-
Administration:Orally administered by gavage; 20 mg/kg; once daily; 12-28 weeks
-
Result:Improved motor function in HD mice.
Chemical Information
-
CAS No. 877963-94-5
-
Appearance Solid
-
분자량 317.41
-
화학식 C16H19N3O2S
-
Color White to off-white
-
SMILES
O=C(C(C=CC=C1)=C1S2)N2CN3CCN(C(C4CC4)=O)CC3
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Irgm1 Improves Postinfarction Cardiac Repair by Promoting Neutrophil Clearance and Efferocytosis. [Abstract]2026 Apr;13(21):e14863. PMID: 41738282
LOC14 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(21):e14863. [Abstract]
LOC14 (10 μM; 16 h) increased the GRP78 protein expression in WT and Irgm1-cKO neutrophils incubated with LPS (2 µg/mL).
LOC14 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(21):e14863. [Abstract]
LOC14 (10 μM; 16 h) increased the GRP78 expression and partial recovery of efferocytosis in WT and Irgm1-cKO neutrophils incubated with LPS (2 µg/mL).
LOC14 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(21):e14863. [Abstract]
LOC14 (10 μM; 16 h) contributed to partial recovery of PtdSer exposure and efferocytosis in WT and Irgm1-cKO neutrophils incubated with LPS (2 µg/mL).
LOC14 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(21):e14863. [Abstract]
LOC14 (20 mg/kg; po; daily for 7 days) increased survival rate of WT and Irgm1‐cKO mice with myocardial infarction (MI).
LOC14 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(21):e14863. [Abstract]
LOC14 (20 mg/kg; po; daily for 7 days) significantly reduced the infarct size in both WT and Irgm1‐cKO mice with myocardial infarction (MI).
LOC14 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Apr;13(21):e14863. [Abstract]
LOC14 (20 mg/kg; po; daily for 7 days) improved efferocytosis of neutrophils in both WT and Irgm1‐cKO mice in the heart in both WT and Irgm1‐cKO mice with myocardial infarction (MI).
-
Schizophr Bull
Protein Disulfide Isomerase A3, a Stress Response Gene, Is Associated with Cognitive Impairment in Schizophrenia and Linked to Inflammatory Activation. [Abstract]2025 Oct 30:sbaf194. PMID: 41165200 -
Int J Antimicrob Agents
Targeting the human protein disulfide isomerase A3 as a broad-spectrum antiviral approach against human respiratory viruses. [Abstract]2026 Apr 2:107802. PMID: 41935586 -
Antiviral Res
Venezuelan equine encephalitis virus E1 protein interacts with PDIA6 and PDI inhibition reduces alphavirus production. [Abstract]2023 Apr:212:105560. PMID: 36822370
LOC14 purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2023 Apr:212:105560. [Abstract]
The CC50 (50% cytotoxic concentration) of LOC14 (0-2.5 µM; 16 h) is 93 μM for Vero cells, 70 μM for U87-MG cells.
-
용액&용해도
DMSO : 50 mg/mL (157.52 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (275 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kaplan A, et al. Small molecule-induced oxidation of protein disulfide isomerase is neuroprotective. Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):E2245-52. [Content Brief]
[2]. Chamberlain N, et al. Lung epithelial protein disulfide isomerase A3 (PDIA3) plays an important role in influenza infection, inflammation, and airway mechanics. Redox Biol. 2019 Apr;22:101129. [Content Brief]
[3]. Zhou X, et al. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease. Hum Mol Genet. 2018 May 1;27(9):1545-1555. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1505 mL | 15.7525 mL | 31.5050 mL | 78.7625 mL |
| 5 mM | 0.6301 mL | 3.1505 mL | 6.3010 mL | 15.7525 mL | |
| 10 mM | 0.3150 mL | 1.5752 mL | 3.1505 mL | 7.8762 mL | |
| 15 mM | 0.2100 mL | 1.0502 mL | 2.1003 mL | 5.2508 mL | |
| 20 mM | 0.1575 mL | 0.7876 mL | 1.5752 mL | 3.9381 mL | |
| 25 mM | 0.1260 mL | 0.6301 mL | 1.2602 mL | 3.1505 mL | |
| 30 mM | 0.1050 mL | 0.5251 mL | 1.0502 mL | 2.6254 mL | |
| 40 mM | 0.0788 mL | 0.3938 mL | 0.7876 mL | 1.9691 mL | |
| 50 mM | 0.0630 mL | 0.3150 mL | 0.6301 mL | 1.5752 mL | |
| 60 mM | 0.0525 mL | 0.2625 mL | 0.5251 mL | 1.3127 mL | |
| 80 mM | 0.0394 mL | 0.1969 mL | 0.3938 mL | 0.9845 mL | |
| 100 mM | 0.0315 mL | 0.1575 mL | 0.3150 mL | 0.7876 mL |
LOC14 Related Classifications
HY-100432 Related Classifications
Powered by Bioz